Clinical Trials · NCT07028320
To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture Risk
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Enrollment
- 493
- Start date
- Dec 2021
- Locations
- 1 site, China
- Primary endpoint
- Percent Change in Bone Mineral Density (BMD) of Lumbar Spine from Baseline to 48 Weeks